GlobeNewswire

Casa Systems Announces Key Customer Deployments at Telefónica Spain, China Mobile and Tier 1 North American Mobile Network Operator

Dela

ANDOVER, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Casa Systems (NASDAQ:CASA), a leading provider of end-to-end network infrastructure technology solutions for wireline and wireless networks today announced deployments with key service providers including Telefónica Spain, China Mobile and a Tier 1 North American mobile network operator (MNO).

China Mobile (CMCC), a global top three wireless service provider with nearly 850 million subscribers, is utilizing Casa's technology to provide connectivity services for enterprise and residential customers. CMCC, working in conjunction with Datang Mobile, was looking for a way to provide 4G connectivity services for enterprise and residential customers. The operator selected Casa's small cell agnostic Axyom(TM) Small Cell Core based on its ability to provide a highly scalable solution for densifying its cellular networks in a cost-effective compact footprint as well as its flexible architecture for the secure transport of small cell traffic. Axyom sits at the network edge and provides China Mobile with plug and play convenience, self-optimizing and self-healing efficiency, and secure backhaul for its deployed network of small cell access points. 

Casa also announced that Telefónica Spain is deploying Casa's 4G Apex(TM) Small Cells and Small Cell management solution to improve in-building quality of service and coverage for residential customers. Telefónica's fixed, mobile and broadband networks reach 349 million commercial and residential access points around the world, most notably across Europe and increasingly throughout Latin America. Telefónica is now focused on expanding the density of its mobile network to accommodate the growing wave of new devices and applications and ensure an optimal subscriber experience. By leveraging small cells in its network strategy, Telefónica will increase network capacity and availability for increasingly demanding customers who are connecting more and consuming more data.

"Our goal is to provide our subscribers with the best possible user experience and to do this, it means our networks must have superior speed, availability and performance," said Gerardo Rovira, Director, Radio Access Network at Telefónica Spain. "With small cell solutions like Casa Systems' Apex small cell portfolio, Telefónica will deliver network density that is capable of meeting growing broadband demand and accessing more data intensive services and applications that our subscribers need."

Additionally, Casa's Apex Small Cell Core was recently selected by a Tier 1 North American Mobile Network Operator to aggregate and manage small cell traffic and signaling across the company's network. The provider needed a cost-effective solution to enhance coverage and the user experience on its network. Casa's solution enables the provider to more cost effectively scale and integrate the small cell traffic with the core network.

"These deployments illustrate why the world's top tier service providers are turning to Casa as their partner of choice for delivering network innovations that will help them prepare for the complex challenges of transitioning to the 5G era," said Jerry Guo, CEO of Casa Systems. 

About Casa Systems, Inc.
Casa Systems, Inc. (NASDAQ:CASA) delivers software solutions that enable wireless and wireline broadband providers to meet the growing demand for gigabit bandwidth and services. We provide a suite of distributed and virtualized solutions for fixed and mobile 5G ultra-broadband networks. Our solutions are commercially deployed in over 70 countries serving more than 400 customers, including regional service providers as well as some of the world's largest Tier 1 broadband service providers.

CONTACT INFORMATION:
Alicia Thomas 
Casa Systems, Inc.   
100 Old River Road
Andover, Mass. 01810  
+1.817.909.8921   
Alicia.thomas@casa-systems.com                         




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Casa Systems, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum